Case report details skin eruption from bortezomib in a newly diagnosed multiple myeloma patient, suggesting need for monitoring.
Abstract The proteasome inhibitor bortezomib is used to treat various hematological cancers. It is currently included in the standard of care for individuals receiving their first line treatment for a recently diagnosed multiple myeloma. Generally well tolerated, bortezomib has been linked to a number of side effects. In this instance, a reticular eruption that developed at the site of a subcutaneous bortezomib administration in a 45-year-old male patient with recently diagnosed multiple myeloma is described along with histological confirmation. After a skin biopsy, it was shown that the perivascular of lymphocytes and eosinophils admixed with neutrophils at dermis with unremarkable hypodermis. The patient responded well to betamethasone dipropionate 0.05% cream treatment.
No takes yet. Share an insight, caveat, or question.
Subedi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: